Kong Mo-Wei, Yu Yang, Wan Ying, Gao Yu, Zhang Chun-Xiang
Department of Cardiology, Southwest Medical University, Luzhou 646000, Sichuan Province, China.
School of Basic Medical Sciences, Southwest Medical University, Luzhou 646000, Sichuan Province, China.
World J Gastrointest Oncol. 2024 Nov 15;16(11):4518-4521. doi: 10.4251/wjgo.v16.i11.4518.
This editorial reviews advances in hepatocellular carcinoma (HCC) treatment, focusing on a triple therapy approach and biomarker discovery. Zhang discuss the synergistic potential of transarterial chemoembolization combined with tyrosine kinase inhibitors and PD-1 inhibitors. Meanwhile, Li identify protein tyrosine phosphatase non-receptor II (PTPN2) as a biomarker for poor prognosis and immune evasion in HCC. The studies highlight the importance of combined therapies and biomarkers in improving HCC treatment efficacy and patient outcomes, with PTPN2 emerging as a potential therapeutic target. This article supplements the aforementioned studies with more recent research advancements, focusing on the molecular mechanisms and clinical applications of biomarkers.
这篇社论回顾了肝细胞癌（HCC）治疗的进展，重点关注三联疗法和生物标志物的发现。张讨论了经动脉化疗栓塞联合酪氨酸激酶抑制剂和PD-1抑制剂的协同潜力。同时，李将蛋白酪氨酸磷酸酶非受体II（PTPN2）确定为HCC预后不良和免疫逃逸的生物标志物。这些研究强调了联合疗法和生物标志物在提高HCC治疗效果和患者预后方面的重要性，PTPN2成为一个潜在的治疗靶点。本文用更新的研究进展补充了上述研究，重点关注生物标志物的分子机制和临床应用。
